Hormonal
Unimolecular GLP1R/GIPR dual agonists (e.g., tirzepatide) produce superior body weight reduction and glycemic improvements compared to GLP-1 receptor agonists alone, driven by GIP receptor signaling in central nervous system GABAergic neurons.
If you are managing obesity or Type 2 Diabetes, dual-acting medications (like tirzepatide) that target both GLP-1 and GIP receptors have shown superior weight loss (up to 20-22%) compared to GLP-1 only drugs. These are taken once weekly. Discuss with your doctor if this option is suitable, noting it may help mitigate some nausea associated with GLP-1 only treatments.
Unimolecular GLP1R/GIPR dual agonists not only amplify the metabolic benefits of GLP-1 therapies but may also reduce common side effects, offering an effective strategy for managing obesity and T2D-related conditions... In phase 3 clinical trials, tirzepatide demonstrated more effective reductions in body weight (approximately 20-22% weight loss with once-weekly 15 mg dosing)... Selective removal of Gipr from GABAergic cells... pointed to the importance of GABAergic neurons for both the protection against DIO and the reduction in food intake in response to systemically applied GIPR-agonists, especially when co-administered with a GLP1R-agonist.
Why this rating
The paper cites Phase 3 clinical trials for tirzepatide and preclinical mechanistic studies, though it notes some controversy regarding specific central mechanisms.
Source
The role of GIPR in food intake control
Paula-Peace James-Okoro et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1532076
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →